StockData
MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31

MARAVAI LIFESCIENCES HOLDINGS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.99+0.20 (+2.95%)

Close on Oct 19, 2026

Market cap
$1.03B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026After market close$51.40M$-0.08$-0.02
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026After market close$65.80M$-0.02$0.01
Q4 FY2025
Ended Dec 31, 2025
Feb 25, 2026After market close$49.90M$-0.24$-0.04
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025After market close$41.60M$-0.18$-0.08
Q2 FY2025
Ended Jun 30, 2025
Aug 11, 2025After market close$47.40M$-0.27$-0.08
Q1 FY2025
Ended Mar 31, 2025
May 12, 2025After market close$46.90M$-0.21$-0.08
Q4 FY2024
Ended Dec 31, 2024
Feb 25, 2025After market close–––
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024After market close$65.20M$-0.70$-0.02
Q2 FY2024
Ended Jun 30, 2024
Aug 7, 2024After market close$73.40M$-0.05$0.00
Q1 FY2024
Ended Mar 31, 2024
May 8, 2024After market close$64.20M$-0.09$-0.02
Q4 FY2023
Ended Dec 31, 2023
Feb 22, 2024After market close$74.10M$-0.80$0.01

Company guidance

Outlook given with results on Aug 6, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Adjusted EBITDA (non-GAAP)non-GAAPfull year 2026$33.00M to $35.00MRaised
Revenuefull year 2026$205.00M to $215.00MMaintained

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Maravai Lifesciences filed with the SEC